Margin reduction in radiotherapy for glioblastoma through ¹⁸F-fluoroethyltyrosine PET? - A recurrence pattern...

¹⁸F-fluoroethyltyrosine (¹⁸F-FET) PET is increasingly used in radiation treatment planning for the primary treatment of glioblastoma (GBM) patients additionally to contrast-enhanced MRI. To answer the question, whether a margin reduction in the primary treatment setting could be achieved through ¹⁸F-FET PET imaging, a recurrence pattern analysis was performed.

GBM patients undergoing ¹⁸F-FET PET examination before primary radiochemotherapy from 05/2009 to 11/2014 were included into the recurrence pattern analysis. Biological tumour volumes were semi-automatically created and fused with MR-based gross tumour volumes (_MRGTVs). The pattern of recurrence was examined for _MRGTVs and for _PET-MRGTVs. The minimal margin including all recurrent tumour sites was assessed by gradual expansion of the _PET-MRGTVs and _MRGTVs until inclusion of all contrast-enhancing areas at recurrence.

36 GBM patients were included to the analysis. The minimal margin including all contrast enhancing tumour at recurrence was significantly smaller for the _PET-MRGTVs compared to the _MRGTVs (median 12.5 mm vs. 16.5 mm; p < 0.001, Wilcoxon-Test). _PET-MRGTVs with 15 mm CTV margins were significantly smaller than _MRGTVs with 20 mm CTV margins (median volume 255.92 vs. 258.35 cm³; p = 0.020, Wilcoxon-Test; excluding 3 cases with large non-contrast enhancing tumours). The pattern of recurrence of _PET-MRGTVs with 15 mm CTV margins was comparable to _MRGTVs with 20 mm CTV margins (32 vs. 30 central, 2 vs. 4 in-field, 2 vs. 2 ex-field and no marginal recurrences).

Target volume delineation of GBM patients can be improved through ¹⁸F-FET PET imaging prior to primary radiation treatment, since vital tumour can be detected more accurately. Furthermore, the results suggest that CTV margins could be reduced through ¹⁸F-FET PET imaging prior to primary RT of GBM.